Business Wire

CA-TALKDESK

16.6.2022 11:32:11 CEST | Business Wire | Press release

Share
Barceló Hotel Group Chooses Talkdesk Contact Center Solution

Talkdesk®, Inc. , a global cloud contact center leader for customer-obsessed companies, has been chosen by Barceló Hotel Group to provide a cloud-based destination to centralize the hospitality brand’s contact center operations and improve customer experience (CX) for their clients.

Barceló Hotel Group is the hotel division of the Barceló Group, a Spanish tourism leader. Founded in 1931 by Simón Barceló, the hospitality company has continued to flourish under the leadership of three generations of the Barceló family. Barceló Hotel Group manages 60,000 guest rooms in more than 270 four- and five-star urban and leisure hotel properties across 24 countries. Their company philosophy of “forward hoteligence” inspires the brand to continue elevating the benchmark for guest experience – earning them recognition as one of the 30 largest hotel brands in the world.

Talkdesk CX Cloud™ , an end-to-end customer experience solution, helped Barceló achieve digital transformation within their contact center. The flexibility and scalability of the Talkdesk platform eased the brand through a critical pivot from geographically siloed contact centers to one centralized virtual hub for managing all customer interactions. Previously, Barceló Hotel Group contact center agents – working from various locations across the globe – were only able to focus on customer inquiries within their own geographic areas. With the Talkdesk solution, every Barceló Hotel Group agent can assist any customer at any time. Talkdesk for Salesforce™ provides agents with real-time access to key customer details, ensuring guest needs are anticipated and met. Individual agents can also access all of their communication channels, tools, and customer data on a single screen, resulting in streamlined workflows and increased efficiency. AI-powered features like Talkdesk Interaction Analytics™ and Talkdesk QM Assist™ offer valuable, real-time coaching opportunities to help agents mine every interaction for the customer insights that lead to outstanding guest experiences.

“The Barceló commitment to excellent guest service is one of the main strategic objectives of the company. It’s not just our vocation, it’s the passion that drives us forward,” said Iñigo Onieva, global digital business director, Barceló Hotel Group. “We also believe that delivering excellent guest experiences, and offering additional value during the reservation process through our contact centers, begins with giving our employees access to the best tools integrated into an omnichannel experience with Barceló.com. The Talkdesk solution presents our contact center agents with a simpler way to leverage complex data and provide a more personalized, seamless guest experience – before, during, and after staying at any one of the hotels managed by Barceló Hotel Group.”

“In hospitality and tourism, the customer journey extends beyond those moments spent enjoying five-star hotel accommodation. The brands who strive to also provide five-star guest experiences – from first inquiry to those thoughtful post-visit touchpoints – will be recognised as pioneers in the quest for guest loyalty,” said Kathie Johnson, chief marketing officer, Talkdesk. “With the Talkdesk solution, Barceló agents will have the capabilities and support needed to guide guests on that complete journey. We’re proud to partner with Barceló in achieving their customer experience goals.”

Additional Resources

  • Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centers

Social Networks

About Talkdesk

Talkdesk® is a global cloud contact center leader for customer-obsessed companies. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye